The "Tri-Medicine Synergy Future Healthcare Conference" took place in Shanghai on April 12–13, co-hosted by China Reform Fund, China Reform Health Management and Services Group Co., Ltd. (China Reform Health), and China Reform Securities Co., Ltd. (China Reform Securities), in partnership with the Zhongguancun JiuTai Clinical Trial Technology Innovation Alliance, the Clinical Trial Industry Technology Innovation Strategic Alliance, and Shanghai General Hospital of Shanghai Jiao Tong University School of Medicine. During the conference, the three co-hosts signed a Strategic Framework Cooperation Agreement with tricision.

The conference theme—"Sowing in Spring, Convergence of Value—Medical Insurance Settlement and Pharmaceutical Innovation"—set the stage for the launch of the Investment and Financing Committee of the Clinical Trial Industry Technology Innovation Strategic Alliance. Discussions spanned the full healthcare ecosystem, exploring payer perspectives, provider value, pharmaceutical integration, and oncology drug innovation. Key topics included universal medical insurance coverage and pharmaceutical innovation strategy, capital allocation in the biopharmaceutical cycle in the post-Diagnosis-Related Group (DRG) era, and the intersection of tumor diagnostics and value-based investment.

Notable attendees included Chen Zhinan, Academician of the Chinese Academy of Engineering and Director of the National Translational Medicine Center for Molecular Medicine at Air Force Medical University; Cao Cai, former Deputy Director of the Center for Inspection and Verification of the National Medical Products Administration (NMPA); Sun Xiaodong, Vice President of Shanghai General Hospital; Li Yonghua, General Counsel and Assistant General Manager of China Reform Holdings, and Party Secretary and General Manager of China Reform Health; Li Hu, Party Committee Member and Deputy General Manager of China Reform Securities; Ma Shaojing, Managing Director of China Reform Fund; and Professor He Youwen, Founder and Chairman of Beijing tricision Biotech Co., Ltd. (tricision). The session was moderated by Liu Yingjie, Deputy Director of the Information Technology Committee of the China Pharmaceutical Quality and Research Association, and Director and Deputy General Manager of China Reform Health.

Liu Yingjie (Director and Deputy General Manager of China Reform Health), Li Hu (Party Committee Member and Deputy General Manager of China Reform Securities), and Zhao Xi (Executive Vice President of tricision) signed the agreement on behalf of their respective organizations.

The partnership is designed to establish a long-term, stable strategic alliance that will explore new business models, enhance competitiveness, and advance each party's strategic objectives. Under the agreement, the three parties will collaborate to accelerate the development of a rapid Research and Development (R&D) and industrialization platform for Messenger RNA (mRNA) technology, positioning it as a critical national capability in response to the fast-moving mRNA drug landscape in China.

China Reform Health will support tricision across multiple dimensions—including investment and financing, big data analytics, Clinical Trial (CT) services, and Investigator-Initiated Trial (IIT) support. China Reform Securities will provide strategic advisory and comprehensive guidance for tricision's Initial Public Offering (IPO), leveraging its capital markets expertise to help navigate the listing process.

About China Reform Health

China Reform Health Management and Services Group Co., Ltd. (stock code: 000503) is a state-owned enterprise listed under China Reform Holdings, specializing in integrated medical insurance management and health security services. The Company focuses on three core areas: medical insurance cost control, medical quality and safety, and pharmaceutical and device supervision. Using advanced technologies such as Artificial Intelligence (AI) and big data, China Reform Health builds professional health security solutions in support of the national "Healthy China" strategy, with a mission to deliver equitable and fair health security services for all.

Centered on the digital transformation of healthcare, China Reform Health has established a leadership position in intelligent medical insurance fund supervision and has achieved broad adoption of the domestically pioneered DRG point-based payment system. Through its unique third-party service model, the Company continues to explore new approaches to "Tri-Medicine Synergy" (medical insurance, healthcare, and pharmaceuticals), advancing the modernization of health security services and integrated fund management.

About China Reform Securities

China Reform Securities Co., Ltd. is a national comprehensive securities firm approved by the China Securities Regulatory Commission (CSRC) and controlled by China Reform Holdings Corporation Limited. With registered capital of RMB 5.841 billion, the Company is headquartered in Beijing and operates 18 branches, 64 sales offices, and 4 subsidiaries. Its business strategy is "research-driven, investment banking-led, with coordinated growth across asset management, wealth management, and proprietary trading." The Company holds a comprehensive license portfolio that includes investment banking, asset management, wealth management, proprietary investment, mutual funds, futures, private equity, and alternative investments, as well as key qualifications in financial product distribution, National Equities Exchange and Quotations (NEEQ) market-making, and stock options.

Looking forward, China Reform Securities aims to integrate into national strategic priorities and state capital operations, guided by the core values of "Compliance, Integrity, Professionalism, and Stability." The Company is committed to providing specialized, one-stop financial services to state-owned enterprises, pursuing a path of distinctive, specialized, and high-quality development.

About tricision

As one of China's earliest biopharmaceutical companies to pursue cellular immunotherapy and mRNA nucleic acid drug innovation, tricision is driven by a single mission: "to transform cancer into a chronic, manageable disease." The Company's development philosophy—"people-oriented, technology for good, innovation-driven, and future-leading"—guides its work across R&D, manufacturing, and clinical translation for mRNA and other nucleic acid therapeutics.

tricision's technology architecture rests on three platforms: "One Body" (nucleic acid technology) and "Two Wings" (Nanodelivery Platform (NP) and Cell Delivery Platform (CDP)). With triVAC and C2 as its flagship patents, tricision has filed 53 invention patents in the mRNA space, 22 of which have been granted. The Company has built robust Chemistry, Manufacturing, and Controls (CMC) capabilities that span raw material enzymes, plasmids, mRNA, and Lipid Nanoparticle (LNP) production. Its pipeline includes multiple mRNA-DC product candidates across several refractory cancers, including pancreatic cancer, triple-negative breast cancer, and osteosarcoma.